BR9812717A - Procesos para expressar uma sequência heterológa em uma célula de tumor, e para tratar câncer em um sujeito, vetor para expressar uma sequência em uma célula de tumor, e, célula hospedeira - Google Patents

Procesos para expressar uma sequência heterológa em uma célula de tumor, e para tratar câncer em um sujeito, vetor para expressar uma sequência em uma célula de tumor, e, célula hospedeira

Info

Publication number
BR9812717A
BR9812717A BR9812717-9A BR9812717A BR9812717A BR 9812717 A BR9812717 A BR 9812717A BR 9812717 A BR9812717 A BR 9812717A BR 9812717 A BR9812717 A BR 9812717A
Authority
BR
Brazil
Prior art keywords
tumor cell
sequence
expressing
processes
vector
Prior art date
Application number
BR9812717-9A
Other languages
English (en)
Other versions
BR9812717B1 (pt
Inventor
Abraham Hochberg
Suhail Ayesh
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of BR9812717A publication Critical patent/BR9812717A/pt
Publication of BR9812717B1 publication Critical patent/BR9812717B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PROCESSOS PARA EXPRESSAR UMA SEQuêNCIA HETEROLóGA EM UMA CéLULA DE TUMOR, E PARA TRATAR CâNCER EM UM SUJEITO, VETOR PARA EXPRESSAR UMA SEQuêNCIA EM UMA CéLULA DE TUMOR, E, CéLULA HOSPEDEIRA". A invenção refere-se à expressão específica de seq³ências heterólogas, particularmente genes que codificam produtos citotóxicos, em células de tumor sob o controle de seq³ências transcricionais reguladoras. Os promotores particularmente preferidos incluem as seq³ências reguladoras de H19, o promotor IGF-1 e os promotores IGF-2 P3 e P4. A invenção proporciona construções de expressão e processos para administrar essas construções de expressão. As composições e processos da invenção são úteis no tratamento do câncer.
BRPI9812717-9A 1997-10-03 1998-10-04 vetor para expressar uma seqüência em uma célula de tumor, e, vetor para expressar uma seqüência heterológa em uma célula de tumor. BR9812717B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94360897A 1997-10-03 1997-10-03
US08/943608 1997-10-03
PCT/IL1998/000486 WO1999018195A2 (en) 1997-10-03 1998-10-04 Methods and compositions for inducing tumor-specific cytotoxicity

Publications (2)

Publication Number Publication Date
BR9812717A true BR9812717A (pt) 2000-08-22
BR9812717B1 BR9812717B1 (pt) 2011-06-28

Family

ID=25479934

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9812717-9A BR9812717B1 (pt) 1997-10-03 1998-10-04 vetor para expressar uma seqüência em uma célula de tumor, e, vetor para expressar uma seqüência heterológa em uma célula de tumor.

Country Status (17)

Country Link
US (2) US6087164A (pt)
EP (1) EP1019499B1 (pt)
JP (3) JP5153031B2 (pt)
KR (1) KR100524262B1 (pt)
CN (1) CN1229496C (pt)
AT (1) ATE407948T1 (pt)
AU (1) AU755774B2 (pt)
BR (1) BR9812717B1 (pt)
CA (1) CA2308124C (pt)
CZ (2) CZ294941B6 (pt)
DE (1) DE69840001D1 (pt)
HU (1) HU228470B1 (pt)
IL (1) IL135430A0 (pt)
NO (2) NO328470B1 (pt)
PL (1) PL339949A1 (pt)
RU (1) RU2214280C2 (pt)
WO (1) WO1999018195A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006220A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of insulin-like growth factor 2 expression
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CA2365901A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DE19928342A1 (de) * 1999-06-21 2000-12-28 Deutsches Krebsforsch Vektoren zur gentherapeutischen Tumorbehandlung
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2002046449A2 (en) * 2000-12-07 2002-06-13 The Penn State Research Foundation Selection of catalytic nucleic acids targeted to infectious agents
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20040005567A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
AU2003241985A1 (en) * 2002-05-31 2003-12-19 Medinet Co., Ltd. Dna inducing cancer cell-specific expression and cancer cell-specific expression vector
US20040180844A1 (en) * 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US7063947B2 (en) * 2004-04-08 2006-06-20 Promogen, Inc. System for producing synthetic promoters
US7429482B2 (en) * 2005-01-13 2008-09-30 United States Of America As Represented By The Department Of Veterans Affairs Screening tools for discovery of novel anabolic agents
EP1915448B1 (en) 2005-07-07 2013-09-04 Yissum Research Development Company, of The Hebrew University of Jerusalem Nucleic acid agents for downregulating h19, and methods of using same
DE602006014009D1 (de) 2005-09-22 2010-06-10 Yissum Res Dev Co Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs
CA2675967A1 (en) * 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusale M Nucleic acid constructs and methods for specific silencing of h19
CA2715080C (en) 2007-09-28 2021-09-28 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
WO2009053982A1 (en) * 2007-10-25 2009-04-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Constructs containing multiple expression cassettes for cancer therapy
EP2298866A4 (en) * 2008-07-02 2013-11-20 Otsuka Pharma Co Ltd ARTIFICIAL KIDNEY PRECURSOR AND METHOD FOR PRODUCING THE SAME
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
EA016223B1 (ru) * 2009-10-07 2012-03-30 Учреждение Российской Академии Наук Институт Молекулярной Генетики Ран Способ и генная конструкция для высокоспецифичного ингибирования нежелательного роста клеток
WO2016178233A1 (en) * 2015-05-05 2016-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
BR112020021962A2 (pt) * 2018-04-30 2021-01-26 Amicus Therapeutics, Inc. construtos para terapia gênica e métodos de uso
CN110714075B (zh) * 2018-07-13 2024-05-03 立森印迹诊断技术（无锡）有限公司 一种用于检测肺肿瘤良恶性程度的分级模型及其应用
CN111206093A (zh) * 2018-11-21 2020-05-29 立森印迹诊断技术（无锡）有限公司 一种用于检测浸润性膀胱癌的标志物及其应用
CN109609505A (zh) * 2019-01-14 2019-04-12 中国科学院成都生物研究所 一种体内筛选的剪切rna的锤头状核酶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699191B1 (fr) * 1992-12-16 1995-02-10 Univ Paris Curie Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IL108879A (en) * 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique

Also Published As

Publication number Publication date
WO1999018195A3 (en) 1999-08-12
AU755774B2 (en) 2002-12-19
EP1019499A2 (en) 2000-07-19
DE69840001D1 (de) 2008-10-23
CA2308124A1 (en) 1999-04-15
WO1999018195A2 (en) 1999-04-15
ATE407948T1 (de) 2008-09-15
JP2001519148A (ja) 2001-10-23
IL135430A0 (en) 2001-05-20
HUP0003745A2 (hu) 2001-02-28
CZ294941B6 (cs) 2005-04-13
CZ20001201A3 (cs) 2000-09-13
BR9812717B1 (pt) 2011-06-28
NO328470B1 (no) 2010-02-22
JP2008136480A (ja) 2008-06-19
JP5153031B2 (ja) 2013-02-27
RU2214280C2 (ru) 2003-10-20
JP2006304801A (ja) 2006-11-09
HUP0003745A3 (en) 2002-04-29
NO20093194L (no) 2000-06-02
CZ294694B6 (cs) 2005-02-16
KR100524262B1 (ko) 2005-10-28
NO20001684L (no) 2000-06-02
HU228470B1 (en) 2013-03-28
NO331723B1 (no) 2012-03-05
AU9457198A (en) 1999-04-27
CN1229496C (zh) 2005-11-30
EP1019499B1 (en) 2008-09-10
US6306833B1 (en) 2001-10-23
CN1280616A (zh) 2001-01-17
US6087164A (en) 2000-07-11
CA2308124C (en) 2008-07-08
KR20010030912A (ko) 2001-04-16
PL339949A1 (en) 2001-01-15
NO20001684D0 (no) 2000-03-31

Similar Documents

Publication Publication Date Title
BR9812717A (pt) Procesos para expressar uma sequência heterológa em uma célula de tumor, e para tratar câncer em um sujeito, vetor para expressar uma sequência em uma célula de tumor, e, célula hospedeira
Robbins et al. Structural and immunological similarities between simian sarcoma virus gene product (s) and human platelet-derived growth factor
BR9612359A (pt) Derivado covalente de uma proteína ob composição polipeptídeo quimérico sequência de ácido nucleico vetor de express o replicável célula hospedeira e métodos associados aos mesmos
Mikami et al. Nuclear protein (s) binding to the conserved DNA hexameric sequence postulated to regulate transcription of wheat histone genes
IL136104A0 (en) Vector for tissue-specific replication and gene expression
FI972225A0 (fi) Vektorit kudosspesifistä replikaatiota varten
JPS6416589A (en) Development of human proapolipoprotein a-1
DE3471688D1 (en) Dna vectors and their use in recombinant dna technology
BR9910814A (pt) Vacina para imunização terapêutica ou profilática contra vìrus da venezuelan equine encephalitis (vee), composição farmacêutica, processo para produção de uma resposta imune protetora contra vìrus vee em um mamìfero, e, vacina multivalente
BR9810248A (pt) Sequências reguladoras para plantas transgênicas.
IE831211L (en) Cloning vectors for expression of exogenous protein
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
HUT68379A (en) Method for modifying the cell, tissue or host tropism of a recombinant microorganism obtained this way and use thereof in medicine and veterinary medicine
Som et al. Identification of a highly conserved domain in the EcoRII methyltransferase which can be photolabeled with S-adenosyl-L-[methyl-3H] methionine. Evidence for UV-induced transmethylation of cysteine 186.
AU1896500A (en) High efficiency mammalian gene expression vectors that contain exogenous promoter and entire 5' untranslated region in the upstream from start codon for inherent gene as transcription regulatory site
DK0817858T3 (da) Vektorer, som indeholder terapeutiske gener for antimikrobielle peptider, til anvendelse ved genterapi
Pellerin et al. Corticotropin-induced secreted protein, an ACTH-induced protein secreted by adrenocortical cells, is structurally related to thrombospondins.
ATE256184T1 (de) Promotor des utrophingens
AU2419599A (en) Reconstituting retroviral vector (recon vector) for targeted gene expression
WO2000078939A3 (de) Vektoren zur gentherapeutischen tumorbehandlung

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/06/2011, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2534 DE 30-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.